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Background: NEUROG3 is a key regulator of pancreatic endocrine cell differentiation in mouse, essential for the
generation of all mature hormone producing cells. It is repressed by Notch signaling that prevents pancreatic cell
differentiation by maintaining precursors in an undifferentiated state.
Results: We show that, in zebrafish, neurog3 is not expressed in the pancreas and null neurog3 mutant embryos do
not display any apparent endocrine defects. The control of endocrine cell fate is instead fulfilled by two basic helix-
loop-helix factors, Ascl1b and Neurod1, that are both repressed by Notch signaling. ascl1b is transiently expressed in
the mid-trunk endoderm just after gastrulation and is required for the generation of the first pancreatic endocrine
precursor cells. Neurod1 is expressed afterwards in the pancreatic anlagen and pursues the endocrine cell
differentiation program initiated by Ascl1b. Their complementary role in endocrine differentiation of the dorsal bud
is demonstrated by the loss of all hormone-secreting cells following their simultaneous inactivation. This defect is
due to a blockage of the initiation of endocrine cell differentiation.
Conclusions: This study demonstrates that NEUROG3 is not the unique pancreatic endocrine cell fate determinant
in vertebrates. A general survey of endocrine cell fate determinants in the whole digestive system among
vertebrates indicates that they all belong to the ARP/ASCL family but not necessarily to the Neurog3 subfamily. The
identity of the ARP/ASCL factor involved depends not only on the organ but also on the species. One could,
therefore, consider differentiating stem cells into insulin-producing cells without the involvement of NEUROG3 but
via another ARP/ASCL factor.
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The pancreas is a mixed gland of the digestive tract
composed of an exocrine compartment (acini and
ducts), releasing digestive enzymes into the duodenum,
and an endocrine compartment, secreting hormones
into the bloodstream in order to control glucose homeo-
stasis. Loss or dysfunction of endocrine insulin-secreting
β-cells leads to diabetes, a widespread disease affecting
more than 370 million people worldwide.
Outstanding progress has been made to set up new
therapies for diabetes through cell therapy (reviewed by
[1-5]). Recent efforts have been focused on directing
stem cells to differentiate in vitro into pancreatic β cells* Correspondence: mvoz@ulg.ac.be
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reproduction in any medium, provided the orthat could be transplanted to diabetic patients [6]. To
achieve that goal, it is essential to understand in detail
the molecular mechanisms controlling pancreatic endo-
crine cell differentiation.
Although much of our knowledge on pancreas organo-
genesis relies on mouse genetic studies, the use of
zebrafish has also significantly contributed to the
deciphering of mechanisms involved in the earliest
phases of pancreas development [7-12]. In this fish, the
endoderm forms two converging sheets of cells by the
end of gastrulation (10 hours post fertilization, hpf).
Subsequently, these cells condense at the midline to
form the endodermal rod which will give rise to the
digestive tract and the associated organs [9,13]. Early in
development, at the 10 somite stage (10s, 14 hpf),
the homeobox Pdx1 factor starts to be expressed in the
endodermal region located between the first and thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tral pancreatic bud will emerge from this pdx1+ region
and will later coalesce to form the pancreas [15]. In
zebrafish, the first hormone-expressing cells that appear
from the dorsal bud are the insulin-producing β-cells,
detected from 15 hpf onward. Next appear the
somatostatin-secreting δ-cells (17 hpf ), the ghrelin ε-
cells (18 hpf ) and finally the glucagon-producing α-cells
(21 hpf). This first wave of endocrine cells is followed by
a second wave coming from the ventral bud that forms
from 32 hpf onwards [15-17]. After that stage, the in-
crease of the endocrine cell mass is believed to result
from the differentiation and proliferation of late forming
ventral bud-derived endocrine cells [16]. Therefore,
while at 2 days post fertilization (dpf), the vast majority
of the endocrine cells is generated from the dorsal bud,
at 12 days, a majority seems to derive from the ventral
bud [16].
Both in zebrafish and mice, the Notch signaling path-
way tightly controls pancreatic cell differentiation. Notch
prevents commitment to the endocrine cell fate, thereby
reserving a population of undifferentiated precursor cells
for ongoing proliferation and generation of later-
appearing cell lineages [18-21]. Notch pathway is a
fundamental and evolutionarily conserved process in
metazoan development. There are numerous core
players that participate in this process. Briefly, via the
Hairy Enhancers-of-split proteins, Notch signaling re-
presses the expression of genes of the Achaete-Scute like
(ASCL) family or of the Atonal related protein (ARP)
family, this latter being subdivided into Atonal,
Neurogenin and Neurod subfamilies. These genes en-
code basic helix-loop-helix (bHLH) transcription factors
and can be classified in two categories, ‘cell fate deter-
minant’ factors and ‘cell differentiation’ factors [22]. The
cell fate determinants are transiently expressed at early
stages and are both necessary and sufficient to initiate
the development of a specific cell lineage. The ‘cell dif-
ferentiation’ factors are expressed at later stages and im-
plement the differentiation program initiated by the cell
fate determinants. For example, in the murine pancreas,
NEUROG3 is the cell fate determinant of the pancreatic
endocrine lineage [23] as its transient expression initi-
ates the endocrine differentiation program of all endo-
crine cells [24-26]. Indeed, almost no endocrine
pancreatic cells were detected in the Neurog3 knock-out
mice [25]. NEUROG3 triggers the sustained expression
of the ‘cell differentiation gene’ Neurod1 that maintains
the endocrine cell differentiation program [27,28].
Homozygous Neurod1 null mice notably have a striking
reduction in the number of insulin-producing β cells
and fail to develop mature islets [29].
The neurog3 gene is found in the zebrafish genome
but, surprisingly zebrafish neurog3 mRNAs were notdetected in the developing pancreas while they were
detected in the hypothalamus and intestine [20,30]. In
this study, we extensively analyzed neurog3 expression
during pancreas development and could not detect any
expression at any stages in this tissue. The lack of
Neurog3 function in the zebrafish pancreas was further
confirmed by analyzing the phenotype of the recently
identified sa211 neurog3 null mutant. As neuronal or
endocrine cell-fate commitment controlled by Notch is
classically carried out via ARP/ASCL factors [31-33], we
next searched for other ARP/ASCL factors acting down-
stream of Notch signaling that would promote the for-
mation of pancreatic endocrine cells. Among the 14
ARP/ASCL factors identified in the zebrafish genome,
only ascl1b and neurod1 were found to be strongly
expressed at early stages of endocrine cell differentiation.
Knock-down analysis reveals that these factors have
complementary roles in endocrine cell differentiation
and that their simultaneous inactivation leads to a loss
of all hormone-secreting cells. These two bHLH factors
are, therefore, playing together a role analogous to that
described for murine NEUROG3.
Results
neurog3 is not expressed in the pancreatic dorsal bud
and null neurog3 mutant embryos do not display any
apparent endocrine defects
To determine whether the fundamental role of Neurog3
in endocrine cell differentiation in mice is conserved in
zebrafish, we first analyzed neurog3 expression in the
pancreas by whole-mount in situ hybridization (WISH).
neurog3 expression was never detected in the pancreas
at any developmental stages tested (14s, 18s, 24 hpf, 30
hpf, 52 hpf, 72 hpf, 4 dpf and 5 dpf) whereas its expres-
sion was found in the hypothalamus and in scattered
cells of the intestine (Figure 1A-B), as reported previ-
ously [20,30]. To ensure that Neurog3 is actually not in-
volved in pancreatic endocrine cell differentiation as
neurog3 expression level could be below the WISH de-
tection limit, we analyzed the pancreas of a novel
zebrafish neurog3 mutant recently identified at the
Zebrafish Mutant Resource [34]. This neurog3 mutant
allele (sa211) harbors an A to T substitution changing
codon 74 (Arg) to a premature stop codon and is pre-
dicted to give rise to a truncated Neurog3 protein lack-
ing the whole bHLH domain. The sa211 should be,
therefore, a null allele. neurog3 homozygous mutant em-
bryos do not display any modifications in the number of
pancreatic endocrine α-, β-, δ- and ε-cells compared to
wild type embryos (Figure 1C). The same result was
obtained when we knocked-down neurog3 expression with
a morpholino targeting its translation start site (Mo1) or
its 5′UTR (Mo2) [see Additional file 1: Figure S1]. As
extensive searches in the zebrafish genome did not
Figure 1 neurog3 is not expressed in the pancreas and null
neurog3 mutant embryos do not display any apparent
endocrine defects. (A-B) Whole-mount in situ hybridization (WISH)
showing expression of neurog3 in the hypothalamus at 30 hpf (A)
and in scattered cells of the gut (dotted lines) at 72 hpf (B). (C)
WISH showing that the number of cells expressing insulin,
somatostatin, ghrelin and glucagon is not changed in the neurog3
sa211 mutants compared to the wt siblings. All views are ventral
with the anterior part to the left. Scale bars : 50 µm hpf, hours post
fertilization; wt, wild type.
Figure 2 ascl1b and neurod1 are expressed during early
pancreas development. (A) Phylogenetic tree calculated with
full-length amino acid sequences from vertebrate members of the
ARP/ASCL family. The pancreatic expression of zebrafish ARP/ASCL
was tested by WISH and the expression levels are depicted by (+++)
highly, (++) moderately, (+) weakly, (−/+) very weakly and (−) not
expressed in the pancreas. (B-C) WISH showing expression of
neurod1 (B) and ascl1b (C) in the pancreatic region at the indicated
stages. All views are ventral with anterior part to the left. Scale bars :
50 µm WISH, whole-mount in situ hybridization.
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indicate that the zebrafish Neurog3 factor does not con-
trol pancreatic endocrine cell fate, in contrast to the mur-
ine NEUROG3, and suggest that another bHLH factor is
playing its role in this fish model.Expression of ARP/ASCL genes in the developing
zebrafish pancreas
In order to identify the functional equivalent of murine
NEUROG3 in zebrafish, we searched for another ARP/
ASCL gene that could assume its role. For that purpose,
we performed a phylogenetic analysis of the various
ARP/ASCL found in the zebrafish genome based on
the bHLH directory described by Wang et al. [35]
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genes in the zebrafish genome, including neurog3 and
another neurogenin gene, neurog1. Extensive in silico
searches did not identify any other neurogenin genes in
the zebrafish genome (see Material and Methods).
The expression of the 14 ARP/ASCL genes was ana-
lyzed by WISH at different time points during pancreas
development (6 to 8s, 12 to 14s, 18 to 20s, 24 hpf, 30
hpf, 48 hpf, 72 hpf). We observed high expression in the
pancreatic region at early stages for only two factors,
namely ascl1b and neurod1 (Figure 2B-C). In contrast,
only weak expression was detected at early stages for
ascl1a, neurog1 and neurod6b within the pancreatic area
[see Additional file 2: Figure S2, A-C], while atoh8 and
neurod6a genes were detected only at late stages, that is,
around two dpf [see Additional file 2: Figure S2, D-E].
neurod1 expression has already been reported in the
dorsal pancreatic bud in zebrafish [20,36-38] but its pre-
cise expression profile was not determined. In this study,
we show that pancreatic neurod1 expression starts
around 6s (12 hpf) in a few cells. At 10s (14 hpf),
neurod1 is expressed in two rows of cells located on
both sites of the midline (Figure 2B). Over the next four
hours, the number of neurod1+ cells progressively in-
creases and they start to cluster to form the islet which
is completely formed at 30 hpf. neurod1 remains
expressed in the pancreas of four dpf larvae as well as in
adults (data not shown).
ascl1b is detected before neurod1 as its expression
starts as early as 10 hpf (bud stage) in two rows of cells
in the prospective pancreatic region (Figure 2C). Over
the following two hours, the number of ascl1b-express-
ing cells increases to reach its maximal level around 12
hpf. Then, ascl1b expression progressively decreases and
is turned off at 17 hpf.
ascl1b and neurod1 are both expressed in the pancreatic
endocrine precursors and their expression is controlled
by Notch signaling
In order to determine in which pancreatic cell types
these two bHLH factors are expressed, double fluores-
cent WISH was performed using probes for other pan-
creatic factors. As mentioned above, ascl1b expression
starts at the end of gastrulation (10 hpf, bud stage) in
the prospective pancreatic region where sox4b, the first
known marker of endocrine precursors, will appear
about two hours later [37,38]. As soon as sox4b is
expressed in the pancreatic anlagen, its expression do-
main overlaps almost perfectly with ascl1b (Figure 3A)
and these two factors remain co-expressed over the next
five hours (Figure 3F and data not shown) until the ex-
pression of ascl1b switches off at 17 hpf. At 12 hpf,
neurod1 starts to be expressed within the sox4b/ascl1b
expression domain (Figure 3B and C). At 14 hpf, pdx1expression is initiated in two bilateral rows of
endodermic cells adjacent to the midline [14]. ascl1b
and neurod1 are expressed within the medial part of the
pdx1 expression domain, which includes the pancreatic
endocrine precursors (Figure 3D and E) [8,9]. From 15
hpf, the two stripes of pancreatic precursors have begun
to coalesce toward the midline starting from the posterior
part (Figure 3F and G) [14,37]. At this stage, neurod1+
cells are still largely included in the ascl1b/sox4b domain
with the exception of a few cells which are only labeled by
neurod1 (arrow in Figure 3G). One hour later, the segrega-
tion of neurod1+ cells from the ascl1b/sox4b endocrine
precursor cells is more striking (Figure 3H). This
separation coincides with the appearance of the first
hormone-expressing cells (that is, insulin-producing cells)
which co-express neurod1 but not ascl1b (Figure 3I, J). At
17 hpf, the expression of ascl1b turns off. In contrast,
neurod1 expression persists and, as shown previously [38],
at 24 hpf neurod1 labels the whole endocrine cell lineage
including the sox4b+ endocrine precursor cells and the
hormone-expressing cells. At 30 hpf, when the majority of
endocrine cells are differentiated and clustered into the
single islet, neurod1 remains expressed in all endocrine
cell types (α, β, δ and ε) (data not shown). All these data
show that ascl1b is transiently expressed in the pancreatic
endocrine precursors and is the earliest pancreatic marker
identified so far (Figure 3K). neurod1 expression is
initiated two hours later in the endocrine precursors and
remains expressed in the mature endocrine cells, in
contrast to ascl1b.
We next asked whether ascl1b and neurod1 could be
mediators of Notch signaling by analyzing their expres-
sion in mind bomb (mib) mutants. mib mutants lack a
Delta-ubiquitin ligase, resulting in the failure to trigger
Delta-mediated Notch signaling [39] and leading to an
increase of endocrine differentiation at early stages
[20,37]. We found that neurod1 and ascl1b expression is
strongly increased in mib pancreas (Figure 4), indicating
that ascl1b and neurod1 expression is repressed by
Notch signaling, further suggesting a role of these two
factors in endocrine differentiation.
Impaired endocrine cell differentiation in neurod1
morphants
To assess the role of Neurod1 in pancreatic endocrine
development, we abrogated Neurod1 protein expression
in zebrafish embryos by injecting two distinct antisense
morpholinos. The first (Mo1-neurod1) targets the trans-
lational start site while the second (Mo2-neurod1) tar-
gets the 5′UTR region. Both morpholinos efficiently
block the translation of the neurod1 transcript as they
completely prevent the expression of GFP from the Tg
(neurod1:egfp) transgenic line [40], while they do not
disturb the overall morphology of the embryos [see
Figure 3 ascl1b and neurod1 are both expressed in pancreatic endocrine precursors. (A-J) Double fluorescent WISH comparing the expression of
ascl1b and neurod1 with the expression of the pancreatic factor sox4b (A, B, F, G), pdx1 (D, E) or with the insulin hormone (I, J) at early stages (12 to 16
hpf). The arrows point to a cell neurod1+/sox4b- (G) or neurod1+/ascl1b- (H). The arrowheads point to a cell neurod1+/ascl1b+ (H). Z-plane confocal
images. All views are ventral with anterior part to the left. (K) Diagram illustrating the time windows for the expression of ascl1b, neurod1 and the
pancreatic hormones. Scale bars : 50 µm hpf, hours post fertilization; WISH, whole-mount in situ hybridization.
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knockdown leads to pancreatic defects as the injection
of each morpholino led to the same phenotype: an al-
most complete depletion of glucagon (α) and ghrelin (ε)
cells (Figure 5G-L) together with a severe reduction inthe number of somatostatin cells (δ) (Figure 5D-F). In
contrast, the number of insulin cells (β) was not signifi-
cantly decreased (Figure 5A-C). As the Mo2 morpholino
was slightly more efficient than Mo1, the following ex-
periments were mainly performed with Mo2.
Figure 4 Pancreatic expression of ascl1b and neurod1 is repressed by Notch signaling. Fluorescent WISH showing pancreatic expression of
ascl1b (A-B) and neurod1 (C-D) in wild-type (wt) embryos (A, C) and mind bomb (mib) mutants (B, D). Confocal projection images. All views are
ventral views of 15 hpf embryos with anterior part to the left. Scale bars : 50 µm hpf, hours post fertilization; WISH, whole-mount in
situ hybridization.
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trols endocrine cell differentiation, we analyzed the ex-
pression of various pancreatic transcription factors in
the neurod1 morphants at 24 hpf. Consistent with the
loss of α-cells, we observed a complete extinction of arx,
a factor known to be expressed specifically in all α-cells
and essential for their differentiation [41] (Figure 6C and
D). In contrast, expression of the mnx1/hb9 gene, specif-
ically involved in β-cell differentiation [36,42] was un-
changed, like insulin (Figure 6A and B). The expression
domain of pax6b and isl1, which at 24 hpf includes all
differentiated hormonal cells [38,43] was clearly reduced
(around two-fold, Figure 6E-H), consistent with α-, ε-
cells loss and a reduced number of δ-cells. Cells still ex-
pressing these two factors correspond to β-cells and to
the residual δ-cells still present in neurod1 morphants
(Figure 6J-L). Since the morpholinos are designed to
prevent neurod1 mRNA translation but not the expres-
sion of the transcripts, we could highlight neurod1+ cells
by WISH in the neurod1 morphants. neurod1+ cells
were present in neurod1 morphants at all stages tested
(14 hpf, 18 hpf, 24 hpf and 30 hpf) and we did not de-
tect any obvious changes in their number compared to
the control morphants (Figure 6P, T, X and data not
shown). This suggests that the loss of α cells in the
neurod1 morphants is not due to the apoptosis of the
neurod1+ cells but due to a blockage in their differenti-
ation process. This was further confirmed by performing
terminal deoxynucleotidyl transferase dUTP nick end la-
beling (TUNEL) assays revealing no apoptotic cells in
the pancreatic area of neurod1 and control morphants at
different stages (26, 30, 40, 48 and 55
hpf) [see Additional file 4: Figure S4 A-D and data
not shown].
To further define neurod1 function in early steps of
endocrine cell differentiation, we analyzed theexpression of sox4b at early stages of development.
While the initiation of sox4b expression is not perturbed
in neurod1 morphants (Figure 6M and O) its expression
is strongly reduced at 18 hpf (Figure 6Q and S) and is
not detectable anymore at 24 hpf (Figure 6U and W).
All together, these data show that, in the absence of
Neurod1, sox4b expression is correctly initiated. Then,
around 17 to 18 hpf, the stage when most β-cells and a
minority of δ-cells are already differentiated (see dia-
gram in Figure 3K), sox4b expression is no longer
maintained and the differentiation of late-appearing
endocrine cells is blocked, leading to a loss of ε- and α-
cells as well as to a reduction of δ-cells.
Impaired endocrine cell differentiation in ascl1b
morphants
Intriguingly, although neurod1 is expressed from 12
hpf (6s) in the pancreatic endocrine precursors,
neurod1 morphants do not display any apparent pan-
creatic defects before 17 hpf. We, therefore, hypothe-
sized that, at early stages, Ascl1b could complement
the loss of Neurod1 function. To test this hypothesis,
we first defined Ascl1b function in endocrine differen-
tiation by injecting an antisense morpholino targeting
the translational start site of ascl1b mRNA as de-
scribed in [44,45].
In contrast to neurod1 morphants, in ascl1b mor-
phants we observed a significant reduction in the num-
ber of all types of pancreatic hormone-expressing cells
(Figure 7). Consistent with this phenotype, we noticed a
reduction of the isl1 expression domain, which includes
all the mature endocrine cells at 24 hpf (Figure 7I, J). As
ascl1a, the paralog of ascl1b, was detected in a few cells
of the endocrine pancreas at 18 hpf [see Additional file
2: Figure S2B], we tested if Ascl1a could have redundant
functions with Ascl1b. This is not the case as the
Figure 5 Impaired endocrine cell differentiation in neurod1 morphants. Ventral views with anterior to the left of WISH showing expression
of insulin (A-C), somatostatin (D-F), ghrelin (G-I) and glucagon (J-L) in control (A, D, G, J), Mo1-neurod1 (B, E, H, K) and Mo2-neurod1 (C, F, I, L)
morphants at 30 hpf. The quantifications on the right side of the figure represent the number of positive cells per embryo for controls and
neurod1 morphants. Asterisks (***) indicate that the difference between cell number in controls and neurod1 morphants is statistically significant
by Student’s t-test (P <0.001). Scale bars : 50 µm hpf, hours post fertilization; WISH, whole-mount in situ hybridization.
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did not lead to a further reduction of endocrine cells
(data not shown).
To further define Ascl1b function, we analyzed the ini-
tiation of endocrine cell differentiation in ascl1b
morphants. At 12 hpf (6s), we could not detect any
sox4b+ cells in the ascl1b morphants whereas sox4b was
easily detectable in control morphants (Figure 8A and
D). At 13 hpf (8s), one or two sox4b+ cells were present
in the ascl1b morphants (Figure 8J), and over the nextfour hours, new sox4b+ cells appeared but their number
never reached the control levels (30% compared to the
control at 17 hpf, Figure 8P). In contrast, neurod1 ex-
pression was correctly initiated in ascl1b morphants
(Figure 8E and K). Interestingly, the few sox4b+ cells
detected in ascl1b morphants were all seen within the
neurod1+ domain (Figure 8L and R) while in control
morphants, a majority of sox4b+ cells do not express
neurod1 (Figure 8C, I and O). These data suggest that,
in ascl1b morphants, sox4b gene expression is switched
Figure 6 Pancreatic cells are arrested in their differentiation process in neurod1 morphants and the expression of sox4b is not
maintained. Ventral views with the anterior to the left of the pancreas of embryos analyzed by visible (C-H, U-X) or fluorescent (A-B, I-T) WISH.
(A-H) Pancreatic expression of mnx1, arx, isl1 and pax6b in controls and Mo2-neurod1 morphants at 24 hpf, the number of isl1+ cells in control
morphant (50.4 ± 2.1) was reduced about 2.1 fold in the Mo2-neurod1 morphant (24.1 ± 1.2) and the number of pax6b+ cells in control
morphant (40.7 ± 1.2) was reduced about 1.8 fold in the Mo2-neurod1 morphant (22.1 ± 1.2). (I-L) Double fluorescent WISH performed with
pax6b (I, J) or isl1 (K,L) probe together with a mix of insulin (ins) and somatostatin (sst) probes on 24 hpf controls or Mo2-neurod1 morphants.
Z-plane confocal images (M-T) Double fluorescent WISH performed with sox4b and neurod1 on 14 hpf and 18 hpf controls or Mo2-neurod1
morphants. Confocal projection images (U-X) WISH performed with sox4b and neurod1 on 24 hpf controls or Mo2-neurod1 morphants. Scale bars
: 50 µm hpf, hours post fertilization; WISH, whole-mount in situ hybridization.
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the onset of sox4b that is detected just after neurod1 ac-
tivation in ascl1b morphants.
Endocrine precursor differentiation is abolished in the
double ascl1b and neurod1 morphants
To test the hypothesis that sox4b expression can be
switched on either through Ascl1b or Neurod1 action, we
performed a co-injection of the morpholinos targeting
both genes. As shown on Additional file 5: Figure S5, this
co-injection does not affect the general morphology of
the embryos. In these double ascl1b/neurod1 morphants,
sox4b expression was never detected, not at 17 hpf
(Figure 9C-D) nor later on (data not shown). Moreover,
this double knock-down abolished all endocrine cell differ-
entiation as we did not detect any hormone-producingcells at early or late stages (17 or 38 hpf) (Figure 10A-J).
In addition, isl1 expression was not detected in the endo-
crine islet at 38 hpf while isl1 was correctly expressed
in the adjacent mesodermal tissue [10] (Figure 9A-B).
Similarly, the expression of pax6b and mnx1 was com-
pletely lost in the endocrine pancreas while pax6b remains
expressed in the neural tube and mnx1 gene in the moto-
neurons and the hypochord (Figure 9G-H). In contrast
to these transcription factors, the ascl1b transcripts
were still detected in the double morphants and the
number of ascl1b positive cells was drastically increased
at 13 hpf (Figure 9E-F) suggesting that these cells
are blocked in their differentiation process. neurod1
transcript was also detected in the double morphants
(Figure 9I-J), confirming the above observations that
neurod1 initiation can occur independently of Ascl1b.
Figure 7 Impaired endocrine cell differentiation in ascl1b morphants. Ventral views with the anterior part to the left of WISH showing
expression of insulin (A-B), somatostatin (C-D), ghrelin (E-F) and glucagon (G-H) in control (A, C, E, G) and ascl1b morphants (B, D, F, H) at 30
hpf. The quantifications on the right side of the figure represent the number of positive cells per embryo for controls and ascl1b morphants. (I-J)
Confocal projections of ventral views of fluorescent WISH showing expression of isl1 in control (I) and ascl1b morphants (J) at 24 hpf. The
quantification of isl1 expression domain is depicted on the right side of the figure. The graph shows the relative volume of isl1+ cells in control
and ascl1b morphants, the mean of the volume occupied by the isl1+ cells in control morphants being arbitrarily set to 100%. Asterisks (***)
indicate that the difference between controls and ascl1b morphants is statistically significant by Student’s t-test (P <0.001). Scale bars : 50 µm hpf,
hours post fertilization; WISH, whole-mount in situ hybridization.
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cells expressing the ascl1b transcripts, we did not ob-
serve any apoptosis at 14s (16 hpf) and 19s (18.5 hpf)
in these double morphants [see Additional file 4: Figure
S4E-H].
Altogether, our data indicate that the simultaneous
loss of ascl1b and neurod1 expression abolishes the for-
mation of all pancreatic hormone-expressing cells by
interfering with the initiation of their differentiationprocess as shown by the loss of the pancreatic expres-
sion of sox4b, isl1, pax6b, mnx1 and arx genes.
ascl1b and neurod1 are also expressed in the endocrine
cells of the ventral bud but not neurog3
As endocrine cells are also generated at later stages from
the intrapancreatic ducts [16,17,47], we investigated
whether Neurog3 could be involved in the generation of
these late endocrine cells. To detect them more easily,
Figure 8 The onset of sox4b expression is delayed in ascl1b morphants and is restricted to neurod1 expressing cells. Ventral views with
the anterior part to the left of double fluorescent WISH showing expression of sox4b and neurod1 at 12 hpf (A-F), 13 hpf (G-L) and 17 hpf (M-R)
in control and ascl1b morphants. The domain occupied by sox4b+ and neurod1+ cells was reduced respectively 3.3- and 2.6-fold in the Mo-ascl1b
at 17 hpf. The arrows point to a cell expressing sox4b and neurod1 while the arrowheads points to a cell expressing only sox4b. Z-plane confocal
images. Scale bars : 50 µm hpf, hours post fertilization; WISH, whole-mount in situ hybridization.
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three to five dpf with the Notch-signaling inhibitor
LY411575, treatment known to drastically increase
the number of endocrine cells coming from the
intrapancreatic ducts (Figure 11A) [17,47,48]. As shown
on Figure 11B, the homozygous neurog3 mutants are
able to generate endocrine cells efficiently from the
intrapancreatic ducts (n = 6), suggesting that Neurog3 is
not involved in the formation of the second wave endo-
crine cells, as it is in the first wave. This is in agreement
with the absence of neurog3 expression in the
intrapancreatic ducts of LY411575-treated embryos (data
not shown). In contrast, we detected a strong expression
of ascl1b in the intrapancreatic ducts of the LY411575-
treated embryos (Figure 11C) as well as of neurod1 as
previously described [48,49], suggesting that the couple
Neurod1 and Ascl1b could also play an important role
in the formation of second wave endocrine cells. The
verification of this hypothesis will require the generation
of ascl1b and neurod1 null mutant as the knock-down of
Neurod1 is no longer fully efficient after 48 hpf.Discussion
In this study, we show that, in zebrafish, Neurog3 does
not control pancreatic endocrine cell fate as it does in
the mouse. This function is fulfilled by two ASCL/ARP
factors, Ascl1b and Neurod1.
Ascl1b starts to be expressed at bud stage (10 hpf) in
the prospective pancreatic region about two hours be-
fore sox4b, that was previously the earliest known
marker of endocrine precursors [37,38,50]. We show
that Ascl1b initiates the pancreatic endocrine cascade
and induces the formation of the first sox4b+ endocrine
pancreatic precursors (see the model in Figure 12A).
Two hours after ascl1b onset, neurod1 expression ap-
pears within the ascl1b/sox4b domain. Neurod1 pursues
the endocrine differentiation program initiated by
Ascl1b notably by maintaining the expression of sox4b
in the precursors and allowing their subsequent differen-
tiation. Indeed, in Neurod1 morphants, sox4b expression
is properly initiated by Ascl1b but, around 17 to 18 hpf,
when ascl1b expression turns off, it is no longer
maintained (Figure 12B). The endocrine differentiation
Figure 9 Simultaneous knock-down of Ascl1b and Neurod1 blocks the differentiation process of the precursors. Ventral views with the
anterior part to the left of the pancreas of control (A,C,E,G,I) or Mo-ascl1b/Mo2-neurod1 morphants (B,D,F,H,J) analyzed by fluorescent (A-D, G-J) or
visible (E-F) WISH. (A-B) Confocal projections of isl1 expression in the pancreatic islet (dotted line) and in the adjacent mesoderm (*) at 38 hpf (C-D)
and of sox4b expression at 17 hpf. (E-F) ascl1b transcript expression at 13 hpf (8s). (G-H) Confocal projections of pax6b (green) and mnx1 (red)
expression at 17.5 hpf showing that the pancreatic expression of pax6b and mnx1 is completely lost in the double morphants. In contrast, the
expression of pax6b in the neural tube and the expression of mnx1 gene in the motoneurons and the hypochord is not perturbed. (I-J) neurod1
transcript expression at 15 hpf (12s). hpf, hours post fertilization; WISH, whole-mount in situ hybridization.
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entiation of later endocrine cells, that is, the majority of
δ (somatostatin), ε (ghrelin) and α (glucagon) cells, nor-
mally appearing, respectively, at 17 hpf, 18 hpf and 21 hpf
(Figure 12B).
The role of Neurod1 as a ‘cell differentiation factor’ re-
quired for the maintenance of the endocrine differentiation
program in zebrafish is similar to the murine situation
where NEUROD1 pursues the endocrine differentiation
program initiated by NEUROG3 and participates in the
maintenance of the mature islet cells (reviewed by [51,52]).
However in zebrafish, if Ascl1b is absent, Neurod1 remains
expressed and acts as a cell fate determinant inducing theformation of the sox4b+ precursors. Indeed, in ascl1b
morphants, sox4b+ precursor cells are detected only after
neurod1 onset and sox4b expression is exclusively induced
in neurod1 expressing cells while, in the control morphants,
the majority of sox4b+ cells do not express neurod1. Conse-
quently, the pool of endocrine precursors is reduced in
Ascl1b morphants, leading to a reduced number of all ma-
ture endocrine cells at 30 hpf (Figure 12C). Thus, in
zebrafish, neurod1 has the capacity to act as a ‘cell fate de-
terminant’ or a ‘cell differentiation’ factor. In mice,
NEUROD1 has been reported to act only as a cell differen-
tiation factor. However, when NEUROD1 is ectopically
expressed in the murine pancreatic anlagen under the
Figure 10 Endocrine cell differentiation is abolished in the double ascl1b and neurod1 morphants. Ventral views of WISH showing
expression of insulin (A-B, I-J), somatostatin (C-D), ghrelin (E-F) and glucagon (G-H) in control (A,C,E,G,I) and Mo-ascl1b/Mo2-neurod1 (B,D,F,H,J)
morphants at 38 hpf (A-H) or 17 hpf (I-J). The quantifications on the right side of the figure represent the number of positive cells per embryo
for controls and double ascl1b/neurod1 morphants. Asterisks (***) indicate that the difference between cell number in controls and double ascl1b/
neurod1 morphants is statistically significant by Student’s t-test (P <0.001). hpf, hours post fertilization; WISH, whole-mount in situ hybridization.
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acity as Neurog3 to induce endocrine differentiation [28].
Such functional equivalence highlighted by a gain-of-func-
tion approach can probably be explained by the fact that
these two factors regulate largely overlapping sets of genes
[27].
This dual capacity to promote the selection of precur-
sors and to regulate some differentiation steps is not re-
stricted to Neurod1 but is shared by many ASCL/ARPfactors. For example, in the olfactory epithelium, Mash1
and Neurog1 are expressed sequentially in the sensory
neuron precursors. MASH1 acts as a cell fate determin-
ant by inducing the olfactory precursors, while Neurog1
acts as a cell differentiation gene by allowing the differ-
entiation of these precursors into sensory neurons. How-
ever, NEUROG1 can partly compensate for the loss of
the determination function of MASH1 in the olfactory
placode, suggesting that NEUROG1 also has the intrinsic
Figure 11 Neurog3 is not involved in the formation of the
second wave endocrine cells. (A-B) Ventral views of
immunohistochemistry against GFP of five dpf wt (A) or neurog3 null
mutant (B) tg(pax6b:GFP) embryos treated from three to five dpf with
the Notch signaling inhibitor LY411575. The generation of pax6b
endocrine cells from the intrapancreatic duct (indicated by a dash line)
is not perturbed in the neurog3 null mutant (n = 6). (C) Confocal
projections of ascl1b (green) and neurod1 (red) expression of four dpf
embryos treated from three to four dpf with the Notch signaling
inhibitor LY411575 showing a strong expression in the intrapancreatic
duct. Anterior part to the left. dpf, days post fertilization; wt, wild type.
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factor in the same tissue [53]. This suggests that the
function of some ARP/ASCL factors is not intrinsically
determined by their protein sequence and their structure
but could be simply dictated by the context (cell type
and timing of expression). This flexibility could be
explained by the strong conservation within the bHLH
domain. Nine of the ten residues predicted to contact
DNA are identical among ARP and ASCL proteins [54]
and, based on in vitro studies, there is no indication of
DNA binding differences between ARP and ASCl pro-
teins [55,56]. Therefore, these factors can regulate over-
lapping sets of genes as described for NEUROG3 andNEUROD1 [27] or for the proneural bHLH factors
Xath5 and XNeuroD [57].
However, in other cases, the protein sequence can be
crucial for the intrinsic properties of ARP/ASCL pro-
teins acting as ‘cell fate determinants’ versus ‘cell differ-
entiation factors.’ For example, in the context of muscle
differentiation, the ‘cell differentiation gene’ Myogenin
(Myog) is less efficient than the ‘cell fate determinant
gene’ Myogenic factor 5 (Myf5) at remodeling chromatin
and activating transcription at previously silent loci [58].
Such specificities can result from their interactions with
specific cofactors. For example, functional divergence
between Ato and Neurog proteins in Drosophila is
encoded by three non-conserved residues in the basic
domain of these bHLH which are responsible for the dif-
ferential interaction with Senseless or MyT1 [59]. Such
cofactors can affect the interaction of the bHLH with
their DNA binding sites and/or modulate their tran-
scriptional activity. Identifying such cofactors will be an
important issue to understand better the transcriptional
properties of ARP/ASCL factors.
The lack of pancreatic defects in the zebrafish neurog3
mutant contrasts with the crucial function of NEUROG3
in the mouse. This raised the question whether the
neurog3 gene studied here is the actual ortholog of the
murine Neurog3 gene. This seems to be the case as ex-
tensive searches in the zebrafish genome revealed the
presence of only two neurogenin genes in zebrafish,
neurog3 and neurog1, neurog3 being the most closely re-
lated to murine and human NEUROG3 and the locus
displaying a conserved synteny with the region of human
chromosome 10 containing NEUROG3 [30]. As the
zebrafish genome is almost completely sequenced [60], it
is highly unlikely that another neurogenin gene exists in
zebrafish but this possibility cannot be totally excluded.
Rather, we show here that the crucial role of murine
NEUROG3 in pancreatic endocrine cell differentiation is
fulfilled in zebrafish by two bHLH transcription factors,
Ascl1b and Neurod1. Indeed, the simultaneous inactiva-
tion of these two bHLH factors leads to a complete loss
of all hormone-secreting cells, as in Neurog3 null mice.
The endocrine cells remain at the precursor stage as
they still express the ascl1b transcripts but none of the
later pancreatic transcription factors, such as sox4b,
pax6b, mnx1, isl1 and arx. During the second endocrine
wave coming from the ventral bud, Ascl1b and Neurod1
probably also play an important role as we have ob-
served a strong expression of these two factors in the
intrapancreatic ducts after Notch inhibition.
This indicates that NEUROG3 is not the only cell fate de-
terminant that can promote pancreatic endocrine cell dif-
ferentiation. Even in the mouse, some rare endocrine cells
can be produced in a NEUROG3-independent manner as
Wang et al. reported a small, yet significant, number of
Figure 12 Model describing the function of ascl1b and neurod1 in pancreatic endocrine differentiation. (A) In wt embryos, Ascl1b initiates
the expression of sox4b in the endocrine precursors at 11 hpf. Then, around 12 hpf, neurod1 expression starts and maintains sox4b expression in
the precursors. The differentiation of the distinct endocrine cell types can take place. (B) In neurod1 morphants, Ascl1b initiates the expression of
sox4b in the endocrine precursors at 11 hpf and maintains sox4b expression until 17 hpf. From that stage, ascl1b expression turns off and sox4b
expression is no longer maintained. The differentiation of the late-appearing endocrine cells is blocked. (C) In ascl1b morphants, sox4b expression
is not initiated at 11 hpf. When Neurod1 starts to be expressed from 12 hpf, it initiates sox4b expression in a reduced number of endocrine
precursors. hpf, hours post fertilization; wt, wild type.
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fore e15.5 [61]. One could, therefore, consider differentiat-
ing stem cells into insulin-producing cells without the
involvement of NEUROG3 but via another ARP/ASCL fac-
tor. Such an assumption is strengthened by the fact that in
the murine stomach, it is ASCL1 which is required for the
differentiation of all endocrine cell types [62] whereas
NEUROG3 is only involved in the differentiation of a sub-
set of these cells [63,64]. In contrast, ASCL1 is only
expressed in a few cells of the murine pancreas and its
knock-out does not disrupt the pancreatic endocrine differ-
entiation [28]. These results highlight the diversity found in
the selection of the ARP/ASCL factors involved in thedetermination and differentiation of the endocrine cells and
show that the choice of these factors depends not only on
the organ considered but also on the species.
Methods
Zebrafish maintenance, mutant lines and LY411575 treatment
Zebrafish (Danio rerio) were raised and cared for
according to standard protocols [65]. Wild-type embryos
from the AB strain were used and staged according to
Kimmel (Kimmel et al., 1995). Homozygous mutants
were obtained by mating heterozygous fish for the mind
bomb (mibta52b) allele [66] and for the neurog3sa211 allele
(ZMP, Zebrafish Mutation Project [34]). The genotyping
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from tails of WISH stained embryos by performing a
PCR using primers 0230 (CCAACACATACCCAGTACC
TC) and O233 (TGATTTGACCTCTGTCGAAC) followed
by a nested PCR, 0231 (GCTTGCAAGAGGTAAGCATC)
and O232 (TGTAATTATGCGCGAATCTC) and by subse-
quent sequencing of the PCR products. The LY411575
treatment was performed by incubating the embryos during
the indicated period with a 10 μm LY411575 solution
(Medchemexpress) and replacing the media every day.
Search in the zebrafish genome of another neurog3
paralog gene
In order to discover all neurog genes present in the
zebrafish genome, we screened the Zv9 Genome assem-
bly using the ensembl genome browser [67] that covers
1.357 Gb in scaffolds placed on chromosomes 1 to 25
and 55 Mb in unassigned scaffolds. This zebrafish se-
quence is considered to be nearly complete. Indeed, out
of a non-redundant set of 21,471 zebrafish cDNAs from
ENA/Genbank, only 120 (0.6%) are not currently found
in Zv9 (that is, these 120 do not have a match at 90%
identity covering at least 10% of their length) [60]). Fur-
thermore, we also screened the nucleotide collection
(nt/nr) from the National Center for Biotechnology
Information (NCBI) [68] that consists of GenBank +
EMBL + DDBJ + PDB + RefSeq sequences. These
databanks have been screened by the program ‘tblastn’
with the consensus amino acid sequence of the basic
domain of vertebrate Neurog3 (RRXKANDRERNR) or
of vertebrate Neurog (RRXKA(D/N)DRERNR), the
amino acid sequence of the bHLH domain of murine
NEUROG3 and of zebrafish Neurog3 and with the con-
sensus amino acid sequence of the bHLH of all Neurog
proteins
(RRXKANXRERXRMHXLNXALDXLRXXLPXFPXDX
KLTKIETLRFAXNYIWALXXTXR). All these searches
identified only 2 neurog genes in the zebrafish genome,
neurog3 (AF181996) and neurog1 (AF017301).
Riboprobes, whole-mount in situ hybridization
Antisense riboprobes were made by transcribing linear-
ized cDNA clones with SP6, T7 or T3 polymerase using
digoxigenin or DNP labeling mix (Roche) according to
the manufacturer’s instructions. They were subsequently
purified on NucAway spin columns (Ambion) and
ethanol-precipitated. The zebrafish ascl1a [69], ascl1b
[69], sox4b [37], isl1 [70], neurod1 [71], pax6b [72],
neurog3 [30], atoh1a [73], atoh1b [73], neurod6a [74],
neurod6b [74], atoh1c [75], atoh7 [76], atoh8 [77],
mnx1/hb9 [42], arx [78], pdx1 [79], insulin [79], somato-
statin 2 (PPS2) [80], ghrelin [81] and glucagon [80]
probes have been described elsewhere. The neurod2,
neurod4 and neurog1 probes were obtained fromImagene clones MAGp998E0411982Q (Pst1, SP6),
IRBOp991C31D (Pst1, T7) and IRBOp991BO232D
(EcoRI, T7), respectively. Single whole-mount and
double fluorescent in situ hybridizations were carried
out as described [37].
For visible WISH, quantifications of the number of cells
were performed by counting the cells under the micro-
scope by focusing successively on each layer of stained
cells. For that purpose, the NBT/BCIP staining was care-
fully monitored in order to avoid an overstaining which
would have prevented us from visualizing the individual
cell boundaries. This method has been validated by
counting the number of isl1-expressing cells at 24 hpf
after a visible WISH or after a fluorescent WISH analyzed
by confocal microscopy; very similar results were found (a
mean of 49 cells counted by the first method and of 47 by
the second) (see Figure 7 in [50]). For fluorescent WISH,
quantifications were performed by determining the vol-
ume occupied by specific cells in control and morphants,
100% being arbitrarily fixed as the mean of the volume oc-
cupied by these cells in control morphants. Cell volume
has been calculated by the program Imaris (Bitplane) on
the confocal images of each embryo.
Whole-mount immunohistochemistry and TUNEL assay
WISH was performed using the following antibodies:
rabbit polyclonal antibody against GFP (1:500; Chemicon),
guinea pig polyclonal antibody against Insulin (1:500;
Biomeda), rabbit polyclonal antibody against Somatostatin
(1:1000; MP Biomedicals). The embryos were fixed with
2% formaldehyde in 0.1 M PIPES, 1.0 mM MgSO4 and 2
mM EGTA overnight at 4°C and washed three times with
PBS/0.3% Triton X-100. The yolk was manually removed,
the embryos permeabilized for one hour with PBS/1% Tri-
ton X-100 and then blocked for two hours in PBS/4%
BSA/0.3% Triton X-100 at room temperature. Both pri-
mary and secondary antibodies were incubated overnight
in the same blocking buffer. Washes were done with PBS/
0.3% Triton X-100 for three hours to remove excess
antibodies.
The fragmented DNA of apoptotic cells was identified
by the TUNEL method, using the Apoptag Apoptosis in
situ detection kit (Chemicon) in which the fragmented
DNA fragments are labeled with digoxigenin-nucleotide,
subsequently recognized by peroxidase coupled anti-
digoxigenin antibody and revealed by incubating with
tyramide-fluorescein isothiocyanate (FITC) substrate.
Briefly, after the WISH, the endogenous peroxidases were
inactivated by incubation for one hour in 3% H2O2 at
room temperature, washed three times in PBS/1% Triton
X-100 and incubated in Equilibration Buffer for one hour.
The terminal deoxynucleotidyl transferase (TdT) reaction
was performed by incubating the embryos in a mixture of
18 μl reaction buffer and 6 μl TdT enzyme overnight at
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buffer for 10 minutes. Then, the embryos were rinsed 3
times for 10 minutes with PBS/0.3% Triton X-100. The
detection was performed by incubating the embryos with
50 μl anti-digoxigenin conjugate (peroxidase) overnight at
4°C, rinsing three times for 10 minutes with PBS/0.3% Tri-
ton X-100 and incubating in 50 μl amplification reagent
(Perkin Elmer). + tyramide-FITC (1/5000) for one hour at
room temperature. After three 15-minute washes in PBS/
0.3% Triton X-100, samples were mounted in Prolong
(Invitrogen) and imaged.
Imaging
Microscope pictures were obtained with an Olympus
DP70 photocamera fixed on a BX60 Olympus micro-
scope. Confocal imaging was performed using a Leica
TCS SP2 inverted confocal laser microscope (Leica
Microsystems, Germany) Digitized images were acquired
using a 63X (NA 1.2) Plan-Apo water-immersion object-
ive at 1024 X 1024 pixel resolution. For multicolor im-
aging, FITC was visualized by using an excitation
wavelength of 488 nm and the emission light was dis-
persed and recorded at 500 to 535 nm. Cy3 was detected
by using an excitation wavelength of 543 nm and the
fluorescence emission was dispersed and recorded at
555 to 620 nm. The acquisition was set up to avoid any
cross-talk of the two fluorescence emissions. Series of
optical sections were carried out to analyze the spatial
distribution of fluorescence, and for each embryo, they
were recorded with a Z-step ranging between 1 and 2
μm. Image processing, including background subtrac-
tion, was performed with Leica software (version 2.5).
Captured images were exported as TIFF and further
processed using Adobe Photoshop and Illustrator CS2
for figure mounting.
Morpholino design and injection
All the morpholinos (Mo) were designed by Gene Tools.
The neurog3 morpholinos are complementary to either
the ATG (Mo1: 5′-GGATCTTGGAGTCATTCTCTTGCA
A-3′) or to the 5′UTR (Mo2: 5′-GCTCGCTCAGTAAAA
CCGAGGTACT-3′). The neurod1 morpholinos are com-
plementary to either the ATG (Mo1: 5′-TTTCCTCGCTG
TATGACTTCGTCAT-3′) or the 5′UTR (Mo2: 5′-CCT
CTTACCTCAGTTACAATTTATA-3′). The ascl1b mor-
pholino, as described by [44,45], is complementary to
the ATG (5′-TCGTAGCGACGACAGTTGCCTCCAT-
3′). A standard control Mo, having the sequence 5′-
CCTCTTACCTCAGTTACAATTTATA 3′ has also been
designed by Gene Tools in a way that it should have
no target and no significant biological activity. A
morpholino directed against p53 mRNA was used to pre-
vent nonspecific apoptosis [82], observed with the ascl1b
morpholino. They were dissolved at a concentration of 3μg/μl in 1× Danieau buffer containing 0.5% of rhodamine
dextran (to follow the microinjection process) and
microinjected at the 1 to 2 cells stage at a dose of 2.5 ng
for Mo1-neurog3, 3 ng for Mo2-neurog3, 3 ng for Mo1
and Mo2 neurod1 and 6 ng for Mo-ascl1b together with
3 ng Mo-p53. For the double knock-down of Ascl1b and
Neurod1, a mix with 6 ng of Mo-ascl1b, 3 ng of Mo2-
neurod1 and 3 ng of Mo-p53 was injected. Injected
embryos were then grown in the presence of 0.003% 1-
phenyl-2-thiourea until the desired stage, fixed overnight
in 4% paraformaldehyde and stored in 100% methanol
before analysis.Additional files
Additional file 1: Figure S1. neurog3 morphants do not display any
apparent endocrine defects. WISH showing that the number of cells
expressing insulin (A-C), somatostatin (D-F) and glucagon (G-I) is not
changed in the Mo1-neurog3 (B,E,H) or Mo2-neurog3 (C,F,I) morphants
compared to the Mo-control (A,D,G) morphants at 30 hpf. All views are
ventral with the anterior part to the left.
Additional file 2: Figure S2. ascl1a, neurod6b, neurog1, atoh8 and
neurod6a are expressed in the pancreatic area. WISH showing expression
of neurog1(A) ascl1a (B), neurod6b (C) neurod6a (D) and atoh8 (E) in the
pancreatic region at the indicated stages. All views are ventral with
anterior part to the left.
Additional file 3: Figure S3. Mo1-neurod1 and Mo2-neurod1
morpholinos efficiently block the expression of GFP from the neurod1:
egfp transgenic line. Lateral views of 26 to 30 hpf tg(neurod1:egfp)
embryos injected with Mo1-neurod1 (A), Mo2-neurod1 (B) or control
morpholinos analyzed by bright field illumination (A,B) or by
epifluorescence illumination (A’,B’) showing that both morpholinos
efficiently block the expression of GFP from the neurod1:egfp transgenic
line [40] without disturbing the general morphology of the embryos.
Additional file 4: Figure S4. TUNEL assays on control and morphant
embryos. (A–D) Confocal image projections of 30 hpf and 40 hpf control
and neurod1 morphants after TUNEL labeling for apoptotic cells (in
green) and immunodetection of insulin cells. The arrows highlight
individual TUNEL+ cells in the neural tube. No TUNEL+ cells were found
in the pancreatic region of control or neurod1 morphants at analyzed
stages. (E–H) Confocal image projections of 14S and 19S control and
ascl1b/neurod1 double morphants after TUNEL labeling for apoptotic cells
(in red) and immunodetection of GFP cells. No TUNEL+ cells were found
in the pancreatic region of control or morphants at analyzed stages.
Somites 1 (S1) to somites 4 (S4) are shown on the panels G and H.
Additional file 5: Figure S5. The double ascl1b/neurod1 morphants do
not display general developmental defects. Bright field views of wt
embryos injected with Mo-ascl1b and Mo2-neurod1 morpholinos (A) or
control morpholinos (B) showing no general developmental defects in
the double morphants at 22 hpf.Abbreviations
ARP: Atonal related protein; ASCL: Achaete-Scute like; bHLH: basic helix-loop-
helix; BSA: Bovine serum albumin; dpf: days post fertilization; FITC: Fluorescein
isothiocyanate; GFP: Green fluorescent protein; hpf: hours post fertilization;
Mo: Morpholino; PBS: Phosphate-buffered saline; PCR: Polymerase chain
reaction; s: somite; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end
labeling; UTR: Untranslated region; WISH: Whole-mount in situ hybridization;
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